Is cannabis addictive? Are there treatments? Answers in New journal’s roundtable discussion
New Rochelle, NY, Jan. 28, 2016 — What are the symptoms, risks, and health consequences of "cannabis use disorder," and what is the status of current research efforts to identify effective treatments for cannabis addiction? The answers to these questions, and whether cannabis is more or less addictive than tobacco or alcohol, are presented in a timely and informative Roundtable Discussion, "Legal or Illegal, Cannabis Is Still Addictive", published in the new peer-reviewed journal Cannabis and Cannabinoid Research, from Mary Ann Liebert, Inc., publishers. The article is available open access on the Cannabis and Cannabinoid Research website.
Roundtable Moderator and Journal Editor-in-Chief Daniele Piomelli, PhD, University of California-Irvine, School of Medicine, leads a vibrant discussion among the distinguished panelists: Margaret Haney, PhD, New York State Psychiatric Institute-Columbia University Medical Center, New York, NY; Alan Budney, PhD, Geisel School of Medicine, Dartmouth College, Lebanon, NH; and Pier Vincenzo Piazza, MD, PhD, Magendie Neurocenter, INSERM, Bordeaux, France.
The Roundtable participants focus on topics such as the specific features of cannabis use disorder, cannabis withdrawal, and the lack of U.S. FDA-approved treatments for cannabis addiction and ongoing clinical trials to test investigational agents and approaches. Dr. Piomelli asks the panelists to respond to the provocative question of whether studies to discover therapies for cannabis addiction should continue.
"Laws and attitudes toward cannabis are changing, and this is a welcome development after so many years of irrational closure," says Dr. Piomelli. "Still, we should not forget that cannabis is a drug and, as such, is far from harmless. This Roundtable explores the addictive potential of cannabis, which both preclinical and clinical studies have now firmly established."
About the Journal
Cannabis and Cannabinoid Research is the only peer-reviewed open access journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. Led by Editor-in-Chief Daniele Piomelli, PhD, the Journal publishes a broad range of human and animal studies including basic and translational research; clinical studies; behavioral, social, and epidemiological issues; and ethical, legal, and regulatory controversies. Complete information is available on the Cannabis and Cannabinoid Research website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Medicinal Food, The Journal of Alternative and Complementary Medicine, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.